In Vitro and in Vivo Evaluation of the Anti-Inflammatory and Antithrombotic Synergy of Vitamin C and Bioflavonoids in Healthy Subjects

Not Applicable

Completed

• Conditions: Cardio-protection

• Registration Number: NCT07061431
• Lead Sponsor: Democritus University of Thrace

Brief Summary

This study aimed to evaluate the antioxidant potential, and especially the anti-inflammatory and antiplatelet biological efficacy and synergy of a high dose (1 g) vitamin C - low dose (50 mg) bioflavonoid (VCF) based supplement using both in vitro approaches and an and in vivo clinical trial in human platelets from healthy subjects administered orally for 1 month the VCF supplement (VCF Group) versus the administration of a 1 g vitamin C supplement (VC Group).

Detailed Description

For the In vivo clinical study, blood samples were collected from all participants at baseline (day 0), prior to supplementation (t = 0), and again after 28 days of daily supplementation of VC or VCF. Platelet aggregation was evaluated using three agonists: platelet activating factor (PAF), ADP, and thrombin. Immediately after collection, blood samples collected in citrate containing monovette tubes were centrifuged at 194 × g for 18 minutes at 24 °C to isolate platelet-rich plasma (PRP). The remaining blood was subsequently centrifuged at 1465 × g for 20 minutes at 24 °C to obtain platelet-poor plasma (PPP). PRP and PPP were separated into distinct tubes for further analysis. For aggregometry assays, 250 μL of PRP containing a magnetic stir bar and 500 μL of PPP without stir bar were transferred to each aggregometer cuvette and placed at the appropriate positions at the aggregometer. Platelet aggregation was quantified by determining the mean EC₅₀ values, representing the concentration of each agonist required to induce 50% platelet aggregation. These values were normalized per gram of total content , vitamin C , and flavonoid content as regarding vitamin C and flavonoid supplement. The change in EC₅₀ values after 28 days of supplementation provided an indication of the supplement's modulatory effect on platelet aggregation

Study Timeline

• Study Start: 2024-10-01
• Primary Completion: 2025-03-31
• Study Completion: 2025-05-31
• Status Verified: 2025-07
• Study First Submitted: 2025-07-02
• Study First Submitted QC: 2025-07-02
• Last Update Submitted: 2025-07-02
• Study First Posted: 2025-07-11
• Last Update Posted: 2025-07-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Subjects should:

• not have a pathological condition related to platelet and leukocyte activity
• not have a chronic pathological condition
• have a normal BMI
• not take medications that have anti-inflammatory and/or antithrombotic effects

Exclusion Criteria

If Subjects

• have a pathological condition related to platelet and leukocyte activity
• have a chronic pathological condition
• not have a normal BMI
• take medications that have anti-inflammatory and/or antithrombotic effects

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Anti-platelet cardio-protective efficacy	1 month	The increase of the EC50 values of PAF/ADP/Thrombin induced platelet aggregation in the VCF Group versus the VC Group

Trial Locations

Locations (1)

School of Chemistry, Faculty of Sciences, Democritus University of Thrace; 🇬🇷 Kavála, Kavala, Greece